Skip to content
Screener

Common Stock at other companies

Eli Lilly logo
Eli LillyLLY
$588M-0.7%
AbbVie logo
AbbVieABBV
$18M0.0%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$1K0.0%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$6K0.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
390M+30.0%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$1K0.0%

Other financials

Income statement

See full
Operating income-$14.9M-49.9%
Net income-$13.7M-190%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$40.1M+702%
Total debt$834.0K-27.7%
Total equity$240.7M+388%
Total assets$253.2M+326%

Cash flow

See full
Operating cash flow-$10.4M-25.5%
CapEx$91.0K+153%
Free cash flow-$10.5M-26.1%

Valuation

See full
Market cap$1.16B+243%
Enterprise value$1.12B+245%

Returns & leverage

See full
Return on equity-30.5%-12.5pp
Debt / equity0.0×
Current ratio19.8×+14.9×

Where this comes from

Reported directly by Corvus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-057100
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (Note 15)
Stockholders’ equity:
Preferred stock: $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; 0 shares issued and outstanding at each of March 31, 2026 and December 31, 2025
Common stock: $0.0001 par value; 290,000,000 shares authorized at March 31, 2026 and December 31, 2025; 84,090,424 and 74,696,629 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively87
Additional paid-in capital667,782474,387
Accumulated other comprehensive loss(1,126)(896)
Accumulated deficit(425,985)(412,293)
Total stockholders’ equity240,67961,205

Item 1. Financial Statements (unaudited)

FAQ

What is Corvus Pharmaceuticals's common stock?
Corvus Pharmaceuticals (CRVS) reported common stock of $8K in Q1 2026.
How has Corvus Pharmaceuticals's common stock changed year-over-year?
Corvus Pharmaceuticals's common stock increased by 14.3% year-over-year, from $7K to $8K.
What is the long-term trend for Corvus Pharmaceuticals's common stock?
Over 5 years (2020 to 2025), Corvus Pharmaceuticals's common stock has grown at a 18.5% compound annual growth rate (CAGR), from $3K to $7K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Corvus Pharmaceuticals's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude